Role of rasagiline in treating Parkinson’s disease: effect on disease progression
Irene A Malaty, Hubert H FernandezUniversity of Florida Movement Disorders Center, Gainesville, FL, USAAbstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s dise...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-05-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/role-of-rasagiline-in-treating-parkinsonrsquos-disease-effect-on-disea-a3160 |
id |
doaj-b49c023afd384f29813c948cae469372 |
---|---|
record_format |
Article |
spelling |
doaj-b49c023afd384f29813c948cae4693722020-11-24T22:44:05ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2009-05-012009default413419Role of rasagiline in treating Parkinson’s disease: effect on disease progressionIrene A MalatyHubert H FernandezIrene A Malaty, Hubert H FernandezUniversity of Florida Movement Disorders Center, Gainesville, FL, USAAbstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson’s Disease Outpatients), and has shown ability to reduce off time in more advanced PD patients with motor fluctuations in two large placebo-controlled trials (Parkinson’s Rasagiline: Efficacy and Safety in the Treatment of “Off”, and Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily). Preclinical data abound to suggest potential for neuroprotection by this compound against a variety of neurotoxic insults in cell cultures and in animals. The lack of amphetamine metabolites provides an advantage over the first generation MAO-B inhibitor selegiline. One large trial has investigated the potential for disease modification in PD patients (Attenuation of Disease progression with Azilect Given Once-daily) and preliminary results maintain some possible advantage to earlier initiation of the 1 mg/day dose. The clinical significance of the difference detected remains a consideration.Keywords: rasagiline, Parkinson’s disease, neuroprotection, selegiline http://www.dovepress.com/role-of-rasagiline-in-treating-parkinsonrsquos-disease-effect-on-disea-a3160 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Irene A Malaty Hubert H Fernandez |
spellingShingle |
Irene A Malaty Hubert H Fernandez Role of rasagiline in treating Parkinson’s disease: effect on disease progression Therapeutics and Clinical Risk Management |
author_facet |
Irene A Malaty Hubert H Fernandez |
author_sort |
Irene A Malaty |
title |
Role of rasagiline in treating Parkinson’s disease: effect on disease progression |
title_short |
Role of rasagiline in treating Parkinson’s disease: effect on disease progression |
title_full |
Role of rasagiline in treating Parkinson’s disease: effect on disease progression |
title_fullStr |
Role of rasagiline in treating Parkinson’s disease: effect on disease progression |
title_full_unstemmed |
Role of rasagiline in treating Parkinson’s disease: effect on disease progression |
title_sort |
role of rasagiline in treating parkinson’s disease: effect on disease progression |
publisher |
Dove Medical Press |
series |
Therapeutics and Clinical Risk Management |
issn |
1176-6336 1178-203X |
publishDate |
2009-05-01 |
description |
Irene A Malaty, Hubert H FernandezUniversity of Florida Movement Disorders Center, Gainesville, FL, USAAbstract: Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson’s Disease Outpatients), and has shown ability to reduce off time in more advanced PD patients with motor fluctuations in two large placebo-controlled trials (Parkinson’s Rasagiline: Efficacy and Safety in the Treatment of “Off”, and Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily). Preclinical data abound to suggest potential for neuroprotection by this compound against a variety of neurotoxic insults in cell cultures and in animals. The lack of amphetamine metabolites provides an advantage over the first generation MAO-B inhibitor selegiline. One large trial has investigated the potential for disease modification in PD patients (Attenuation of Disease progression with Azilect Given Once-daily) and preliminary results maintain some possible advantage to earlier initiation of the 1 mg/day dose. The clinical significance of the difference detected remains a consideration.Keywords: rasagiline, Parkinson’s disease, neuroprotection, selegiline |
url |
http://www.dovepress.com/role-of-rasagiline-in-treating-parkinsonrsquos-disease-effect-on-disea-a3160 |
work_keys_str_mv |
AT ireneamalaty roleofrasagilineintreatingparkinsonamprsquosdiseaseeffectondiseaseprogression AT huberthfernandez roleofrasagilineintreatingparkinsonamprsquosdiseaseeffectondiseaseprogression |
_version_ |
1716474883494379520 |